Stabilizing Mutant PAH Proteins with Small Molecule Compounds

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for phenylketonuria (PKU), such as a Phe-restricted diet and medications like Kuvan and Pegvaliase, are challenging due to their restrictive nature and limitations in effectiveness for all patients.

Innovation Solution

Development of compounds of Formula I, which are designed to stabilize mutant phenylalanine hydroxylase (PAH) proteins, thereby reducing phenylalanine levels in patients with PKU. These compounds can be used in pharmaceutical compositions and methods for treating PKU.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If a Phe-restricted diet is used to treat PKU, then blood Phe levels are controlled, but patient quality of life deteriorates due to dietary restrictions

Engineering Contradiction:

Improveblood Phe level controlVSAvoiddietary adherence

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent uses small molecule compounds as intermediaries that bind to mutant PAH proteins and stabilize their structure, enabling the defective enzyme to function properly. This mediator approach allows patients to process phenylalanine normally without requiring strict dietary restrictions, thus resolving the contradiction between effective Phe control and quality of life

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If Kuvan (sapropterin dihydrochloride) is administered to increase BH4 cofactor, then PAH activity is enhanced in some patients, but it is ineffective for patients with certain PAH mutations

Engineering Contradiction:

ImprovePAH activity enhancementVSAvoideffectiveness across mutation types

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent employs structure-based drug design to develop compounds with specific molecular parameters (hydrophobic interactions, hydrogen bonding, steric complementarity) that match the binding pockets of various PAH mutations. By optimizing these physical-chemical parameters, the compounds can stabilize diverse mutant proteins regardless of the specific mutation type, thereby improving adaptability across different patient populations

Inventive Principle:

Principle #35Parameter changes

3Reliability

If Pegvaliase (enzyme substitution therapy) is used to reduce Phe levels, then Phe conversion is achieved, but rapid degradation of the infused protein occurs requiring frequent high-dose injections

Engineering Contradiction:

ImprovePhe reductionVSAvoidprotein stability in vivo

Core Design Contradiction:

ReliabilityVSDuration of action of stationary object

Solution Approach 1:

The patent develops small molecule compounds that can be administered orally and act as persistent stabilizers of PAH protein. Unlike the protein-based Pegvaliase that degrades rapidly, these small molecules have appropriate pharmacokinetic properties allowing for less frequent dosing while maintaining therapeutic effect, thus resolving the duration of action problem

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

4Reliability

If numerous high-dose injections are administered to maintain therapeutic Phe levels with Pegvaliase, then effective Phe reduction is achieved, but treatment cost increases

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidtreatment cost

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent develops small molecule compounds with favorable pharmacokinetic profiles that allow for less frequent administration compared to Pegvaliase. These orally available compounds reduce the need for frequent high-dose injections, thereby lowering treatment costs while maintaining therapeutic effectiveness

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The compounds effectively stabilize mutant PAH proteins, leading to reduced phenylalanine levels in patients with PKU, thereby addressing the limitations of current treatments.

Implementation Method 1

compounds of Formula I, which are designed to stabilize mutant phenylalanine hydroxylase (PAH) proteins

Methodology Applied

Scientific EffectProtein stabilization:

Data Source

PatentUS20250171438A1Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations

Publication Date: 2025.05.29 AGIOS PHARMACEUTICALS INC

AI summary

The disclosure relates to compounds of Formula I or a pharmaceutically acceptable salt thereof, wherein, m, R1-R5, R5A, and L are defined herein. These compounds are useful in methods for stabilizing a mutant PAH protein or reducing blood phenylalanine concentration in a subject suffering from phenylketonuria. In some embodiments, the mutant PAH protein contains at least one R408W, R261Q, R243Q, Y414C, L48S, A403V, I65T, R241C, L348V, R408Q, or V388M mutation. In other embodiments, the mutant PAH protein contains at least one R408W, Y414C, I65T, F39L, R408Q, L348V, R261Q, A300S, or L48S mutation.